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MBackground: Apremilast works intracellularly to regulate inflammatory mediators.Objective: ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe
plaque psoriasis.Methods: This phase III, multicenter, double-blind, placebo-controlled study randomized adults (2:1) to
apremilast or placebo. At week 16, the placebo group switched to apremilast through week 32, followed by
a randomized treatment withdrawal phase to week 52. Binary end points were analyzed using x2 test;
continuous end points used analysis of covariance.Results: In all, 844 patients were randomized (n = 282, placebo; n = 562, apremilast). At week 16,
significantly more patients taking apremilast achieved 75% or greater reduction from baseline Psoriasis Area
and Severity Index score (PASI-75) (33.1%) versus placebo (5.3%, P \ .0001; primary end point). Most
(61.0%) patients rerandomized to apremilast at week 32 achieved PASI-75 at week 52 versus 11.7%
rerandomized to placebo. Of patients rerandomized to apremilast at week 32, mean percentage change
from baseline PASI score was 88% to 81% (weeks 32-52). During the placebo-controlled period, 55.7%
and 69.3% of patients randomized to placebo and apremilast, respectively, had 1 or more adverse events.
Most adverse events were mild/moderate in severity. No new significant adverse events emerged with
continued apremilast exposure versus the placebo-controlled period.Limitations: Data were limited to 52 weeks and may not generalize to nonplaque psoriasis.Probity Medical Research, Waterlooa; Dermatologikum
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d Many psoriasis patients discontinue
treatment because of ineffectiveness,
intolerability, or injection issues.
d In ESTEEM 1, oral apremilast was
effective in moderate to severe plaque
psoriasis for up to 52 weeks and was well
tolerated.
d Apremilast offers an oral treatment
option for patients with psoriasis.Cyclic adenosine mono-
phosphate, a key modulator
of immune cell responses,
is predominantly regulated
by phosphodiesterase 4
(PDE4).1 Apremilast, an oral
PDE4 inhibitor, works intra-
cellularly to regulate inflam-
matory mediators, including
pathways relevant to the
pathogenesis of psoriasis.2
PDE4 inhibition elevates
intracellular cyclic adenosine
monophosphate, which in
turn down-regulates the in-
flammatory responses within T helper (Th) 1, Th17,
and type 1 interferon pathways and modulates
production of anti-inflammatory cytokines, such as
interleukin (IL)-10. In clinical studies, apremilast
treatment decreased the number of myeloid den-
dritic cells and T cells infiltrating the epidermis and
dermis of psoriatic lesions and caused a significant
reduction in gene expression of IL-12/IL-23p40,
IL-22, IL-8, beta-defensin 4, myxovirus resistance
protein 1, IL-17A, and IL-23p19.3,4 PDE4 inhibition
can also affect other organ systems, such as
adipose tissue, which may contribute to effects
such as weight loss.5,6 Apremilast (Otezla, Celgene
Corporation, Summit, NJ) was approved by the US
Food and Drug Administration (FDA) in 2014 and by
the European Commission in 2015 for treatment of
psoriasis and psoriatic arthritis.7,8 Apremilast is the
first oral drug to receive FDA approval for psoriasis
since 1996.9-12
The Efficacy and Safety Trial Evaluating the Effects
of Apremilast in Psoriasis (ESTEEM) phase III pro-
gram comprises 2 randomized, placebo-controlled
studies evaluating apremilast in patients with
moderate to severe plaque psoriasis. This article
reports results of ESTEEM 1.
METHODS
Patients
Patients aged 18 years or older were eligible if
they had chronic plaque psoriasis defined as a
Psoriasis Area and Severity Index (PASI) score of 12
or higher, body surface area involvement 10% or
more, static Physician Global Assessment (sPGA)
score of 3 or higher (moderate to severe), and were
candidates for phototherapy/systemic therapy. Mainexclusion criteria were: other
clinically significant or major
uncontrolled disease, signifi-
cant infection, active or his-
tory of incompletely treated
tuberculosis (testing for
latent tuberculosis was not
required), use of biologics
within 12 to 24 weeks, use
of active topical agents for
psoriasis within 2 weeks, and
prolonged sun or ultraviolet
exposure.
The following topical
therapies were permittedexcept within 24 hours before each visit: weak or
low-potency topical corticosteroids (class 6 or 7)
restricted to treatment of face, axillae, and groin
psoriasis lesions; coal tar shampoo and/or salicylic
acid for scalp lesions; and unmedicated moistur-
izers. Patients previously treated with photother-
apy/systemic therapy (small molecule or biologic)
including treatment failures were permitted in the
study. Live vaccinations were permitted during the
study.
Study design and treatment regimens
ESTEEM 1 (registered on clinicaltrials.gov
NCT01194219; PSOR-1) was a phase III, multicenter,
randomized, double-blind, placebo-controlled study
conducted from September 2010 to December 2012
at 72 sites and consisted of 3 treatment periods
(periods A, B, and C) (Fig 1). In period A (placebo-
controlled phase, weeks 0-16), eligible patients were
randomized (2:1) to apremilast at 30 mg twice a day
or placebo. During period B (maintenance phase,
weeks 16-32), placebo patients were switched to
apremilast, with titration. Apremilast dosing was
maintained from weeks 16 through 32. In period C
(treatment withdrawal phase, weeks 32-52), patients
initially randomized to apremilast at baseline who
achieved 75% or greater reduction from baseline
PASI score (PASI-75) at week 32 were rerandomized
(1:1, blinded) to continue apremilast or switch to
placebo. To mitigate potential dose-dependent
adverse events (AEs), apremilast was titrated in 10-
mg increments (beginning with 10 mg once daily)
over the first week. Patients rerandomized to pla-
cebo at week 32 resumed apremilast (without
titration) when they lost PASI-75 response. Patients
Abbreviations used:
AE: adverse event
ESTEEM: Efficacy and Safety Trial Evaluating the
Effects of Apremilast in Psoriasis
FDA: Food and Drug Administration
IL: interleukin
PASI: Psoriasis Area and Severity Index
PASI-75: 75% or greater reduction from baseline
Psoriasis Area and Severity Index score
PDE4: phosphodiesterase 4
SAE: serious adverse event
sPGA: static Physician Global Assessment
Th: T helper
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achieved PASI-75 at week 32 were maintained on
apremilast through week 52. For patients initially
randomized to placebo or apremilast who did not
achieve a PASI-75 response at week 32 (n = 135,
placebo; n = 245, apremilast), topical therapies/
ultraviolet B could be added at the discretion of the
investigator. Of these patients, 91 (67.4%) in the
placebo group and 126 (51.4%) in the apremilast
group received either a topical or ultraviolet B
therapy during period C; the results for these patients
are not reported in this article. Blinding was main-
tained until all patients discontinued or completed
the week 52 visit. Patients were eligible to continue
in a long-term extension to receive apremilast for up
to 4 additional years. Patients who completed or
discontinued early entered a 4-week posttreatment
observational phase. Visits occurred at baseline and
then every 4 weeks, with an additional visit 2 weeks
after each randomization.
The primary efficacy end pointwas the proportion
of patients achieving PASI-75 at week 16 with
apremilast versus placebo. The major secondary
efficacy end point was the proportion of patients
achieving sPGA score of 0 (clear) or 1 (almost clear)
with a point reduction of 2 or more from baseline at
week 16 with apremilast versus placebo. Safety
evaluations, including AEs, vital signs, laboratory
evaluations, physical examinations, electrocardio-
grams, and chest radiographs, were performed.
Patients provided written informed consent
before study-related procedures were performed,
and the protocol and consent were approved by
institutional review boards or ethics committees at all
investigational sites. The study was conducted in
accordance with the principles of Good Clinical
Practice and the Declaration of Helsinki.Statistical analysis
Efficacy data were assessed for the full analysis set
(all randomized patients). The safety populationcomprised all randomized patients who received 1
dose or more of study drug. Approximately 825
patients were planned to be randomized into the
study to provide a sufficient safety database. This
proposed sample size provided more than 90%
power to detect a 20% difference between apremilast
and placebo in PASI-75 response.
Statistical analyses were conducted in a hierarchi-
cal manner for the efficacy end points to control the
overall type I error rate. Thus, end points were
analyzed in sequence only if the previous end point
was statistically significant. Descriptive statistics
were provided to summarize end points not
included in the prespecified step-down procedure.
All analyses are 2-sided. Discrete variables were
analyzed using a x2 test and an analysis of covariance
model with treatment as a factor and baseline value
as a covariate was used for continuous variables. The
time to loss of PASI-75 response was characterized
using Kaplan-Meier estimates. Missing data were
handled with the last-observation-carried-forward
methodology for the primary and major secondary
end points; multiple sensitivity analyses (including
nonresponder imputation) were conducted to
confirm the robustness of the study results. Safety
end points were summarized using descriptive
statistics. All statistical analyses were conducted
using SAS, Version 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
In all, 844 patients were randomized: 282 to
placebo and 562 to apremilast (Fig 2). Most patients
were from North American sites. Demographic and
baseline characteristics are presented in Table I. At
baseline, mean (SD) PASI score was 19.4 (7.4)
and 18.7 (7.2) for placebo and apremilast,
respectively; mean (SD) psoriasis duration was 18.7
(12.4) and 19.8 (13.0) years, respectively. In the
placebo and apremilast groups, respectively, 150
(53.2%) and 301 (53.6%) patients had been treated
previously with systemic therapy, including 80
(28.4%) and 162 (28.8%) who had received biologics;
101 (35.8%) and 196 (34.9%) patients had not
previously received systemic therapy/phototherapy,
respectively.
Period A (weeks 0-16)
Significantly more apremilast-treated patients
(33.1%) achieved the primary end point (PASI-75 at
week 16) than did placebo patients (5.3%) (95%
confidence interval 23.1%-32.5% for difference be-
tween apremilast and placebo of 27.8%; P\ .0001)
(Table II). sPGA score of 0 or 1 with a point reduction
of 2 or more from baseline at week 16, the major
secondary end point, was achieved by significantly
Fig 1. Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis 1 study design.
*Doses of apremilast were titrated during the first week of administration and at week 16 when
placebo patients were switched to apremilast. xPatients restarted apremilast at the time of loss
of effect versus baseline (loss of 75% or greater reduction from baseline Psoriasis Area and
Severity Index score [PASI-75]) but no later than week 52. zPatients initially on placebo or
randomized to apremilast 30 mg twice a day (BID) who did not attain a PASI-75 were able to
add topicals and/or ultraviolet (UV) B phototherapy at week 32 at the discretion of the
investigator.
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vs 3.9%) (95% confidence interval 13.7%-21.9%
for difference between apremilast and placebo of
17.8%; P\ .0001). Sensitivity analyses conducted to
assess the impact of missing data (including non-
responder imputation) also produced significantly
greater responses (P\.0001) for PASI-75 and sPGA.
Of the other efficacy end points in the
hierarchical testing sequence, the first 7 were
statistically significant (all P\ .0001) (Table II). At
week 16, apremilast resulted in significantly greater
improvement (P\.0001) compared with placebo in
the following efficacy end points: mean percentage
change in body surface area, mean percentage
change in PASI score, 50% reduction from baseline
PASI score, mean change in pruritus visual analog
scale score (mm), and mean change in Dermatology
Life Quality Index score (Table II). There was an
approximately 50% decrease in severity of pruritus at
week 16. In addition, the mean percentage change in
Nail Psoriasis Severity Index and Scalp Physician
Global Assessment responses were significantly
greater for apremilast than for placebo (P\ .0001)in patients with nail and scalp psoriasis at baseline
(Fig 3 and Table II).Period B (weeks 16-32)
Higher response rates were observed at week 32
versus week 16 for PASI-75 response (Fig 4, A), mean
percentage change from baseline in PASI score
(Fig 4, B), and pruritus visual analog scale score
(Fig 4, C ) among patients who were switched from
placebo to apremilast at week 16.Period C (weeks 32-52)
In all, 154 patients randomized to apremilast at
baseline (period A) who achieved PASI-75 response
at week 32 were rerandomized (1:1) to continue
apremilast or switch to placebo. Of the 77 patients
rerandomized to apremilast at week 32, 47 (61.0%)
had PASI-75 response at week 52, and 58 (75.3%) had
70% or more improvement in PASI score from
baseline. Mean percentage change from baseline
PASI scorewas88% to81% fromweeks 32 to 52 in
these patients (Fig 5, A).
Fig 2. Patient disposition. *One death occurred in a patient randomized to apremilast after
receiving the last dose of study medication in the placebo-controlled phase. The patient was
considered to have completed the placebo-controlled phase. xIncludes 4 patients who had a
75% or greater reduction from baseline Psoriasis Area and Severity Index score, were
erroneously not rerandomized, and completed the study. BID, Twice a day.
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Table I. Baseline demographics and disease characteristics: all randomized patients (N = 844)
Placebo n = 282 Apremilast 30 mg BID n = 562
Age, mean (SD), y 46.5 (12.7) 45.8 (13.1)
Male, n (%) 194 (68.8) 379 (67.4)
Female, n (%) 88 (31.2) 183 (32.6)
Race, n (%)
White 250 (88.7) 507 (90.2)
Asian 16 (5.7) 28 (5.0)
Black 10 (3.5) 18 (3.2)
Other 6 (2.1) 9 (1.6)
Body mass index, mean (SD), kg/m2 31.3 (7.4) 31.2 (6.7)
Weight, mean (SD), kg 93.7 (23.2) 93.2 (21.4)
Duration of plaque psoriasis, mean (SD), y 18.7 (12.4) 19.8 (13.0)
PASI score, mean (SD) 19.4 (7.4) 18.7 (7.2)
PASI score #20, n (%) 195 (69.1) 404 (71.9)
PASI score[20, n (%) 87 (30.9) 158 (28.1)
Body surface area, mean (SD), % 25.3 (14.6) 24.4 (14.7)
Body surface area #20%, n (%) 133 (47.2) 296 (52.7)
Body surface area[20%, n (%) 149 (52.8) 266 (47.3)
sPGA score 3 [moderate], n (%) 192 (68.1) 401 (71.4)
sPGA score 4 [severe], n (%) 89 (31.6) 161 (28.6)
Pruritus VAS score, mean (SD), mm 65.2 (24.8) 66.2 (25.5)
DLQI score, mean (SD) 12.1 (6.7) 12.7 (7.1)
Presence of nail psoriasis at baseline, n (%) 195 (69.1) 363 (64.6)
ScPGA score $3, n (%) 189 (67.0) 374 (66.5)
Prior systemic therapy [conventional and/or biologics], n (%) 150 (53.2) 301 (53.6)
Prior conventional systemic therapy, n (%) 102 (36.2) 212 (37.7)
Prior biologic therapy, n (%) 80 (28.4) 162 (28.8)
n = number of randomized patients; actual number of patients available for each parameter may vary.
BID, Twice a day; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; ScPGA, Scalp Physician Global Assessment;
sPGA, static Physician Global Assessment; VAS, visual analog scale.
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(83.1%) lost PASI-75 response and reinitiated
apremilast before week 52; of these, 45 (70.3%)
regained PASI-75 response after retreatment
(retreatment time: 3.4-22.1 weeks). Median time to
first loss of PASI-75 after rerandomization at week 32
was 5.1 weeks (95% confidence interval 4.1-8.1) for
patients who lost response.
Among patients initially randomized to placebo
and switched to apremilast at week 16, 43 of
73 (58.9%) had PASI-75 at week 52. Mean (SD)
percentage change in PASI score from baseline in
these patients was 80.0% (14.4) (Fig 5, B).
In period A, 157 of 282 (55.7%) placebo patients
and 388 of 560 (69.3%) patients taking apremilast had
1 or more AE (Table III). AEs were mild (reported in
31.2% of placebo and 39.5% of apremilast patients) or
moderate (reported in 21.3% of placebo patients and
26.3% of apremilast patients) in severity. Severe AEs
occurred in 9 (3.2%) placebo patients and 20 (3.6%)
apremilast patients. Serious AEs (SAEs) occurred in 8
(2.8%) placebo patients and 12 (2.1%) apremilast
patients.Less than 8% of AEs led to drug discontinuation
across the treatment groups. The most common AEs
(occurring in $5% of patients in the placebo and
apremilast treatment groups) were diarrhea, nausea,
upper respiratory tract infection, nasopharyngitis,
tension headache, and headache (Table III). In
apremilast-treated patients reporting diarrhea and
nausea, 72.4% and 77.4%, respectively, occurred
within 2 weeks after the first dose, 79.0% for diarrhea
and 76.1% for nausea were mild in severity, and
61.0% for diarrhea and 65.6% for nausea resolved
within 1 month. One patient each (0.4%) receiving
placebo reported severe nausea and severe diarrhea,
and 2 each (0.4%) receiving apremilast reported
severe nausea and severe diarrhea.
Exposure-adjusted incidence of AEs did not
increase over time in patients with 1 or more SAE,
and no new significant AEs emerged with continued
apremilast exposure compared with the placebo-
controlled period (period A). In all, 633 (78.7%)
patients had 1 or more AE; the most common AEs
($5%) were the same as those reported during the
placebo-controlled period (Table III). SAEs were
Table II. Clinical response across efficacy end points
Placebo-controlled phase (wk 16)
Placebo n = 282 Apremilast 30 mg BID n = 562
Primary end point, n (%)
PASI-75 (LOCF) 15 (5.3) 186 (33.1)*
PASI-75 (NRI) 14 (5.0) 183 (32.6)
Major secondary end point, n (%)
sPGA response (LOCF)y 11 (3.9) 122 (21.7)*
sPGA response (NRI)y 11 (3.9) 118 (21.0)
Additional end points
Percentage change in psoriasis affected BSA, mean (SD) 6.9 (38.9) 47.8 (38.4)*
Percentage change in PASI score from baseline, mean (SD) 16.7 (31.52) 52.1 (32.81)*
PASI-50, n (%) 48 (17.0) 330 (58.7)*
Change in pruritus VAS score [mm], mean (SD)z 7.3 (27.08) 31.5 (32.43)*
Change in total DLQI score from baseline, mean (SD) 2.1 (5.69) 6.6 (6.66)*
Patients with nail psoriasis at baseline n = 195 n = 363
Percentage change in NAPSI from baseline, mean (SD)x 6.5 (60.57) 22.5 (54.86)*
Patients with scalp psoriasis at baseline n = 189 n = 374
ScPGA score 0 (clear) or 1 (minimal), n (%){ 33 (17.5) 174 (46.5)*
Other end points#
PASI-90, n (%) 1 (0.4) 55 (9.8)
NAPSI-50, n (%)x 29 (14.9) 121 (33.3)
Patients with baseline DLQI[5 n = 236 n = 459
DLQI response, n (%)k 79 (33.5) 322 (70.2)
DLQI response 1 PASI-50 response, n (%)** 26 (11.0) 221 (48.1)
Patients achieving DLQI #5, n (%) 54 (23.6) 251 (55.2)
Wk 16 missing data were handled with LOCF methodology.
BID, Twice a day; BSA, body surface area; DLQI, Dermatology Life Quality Index; LOCF, last observation carried forward; NAPSI, Nail Psoriasis
Severity Index; NAPSI-50, $50% improvement from baseline Nail Psoriasis Severity Index score; NRI, nonresponder imputation; PASI, Psoriasis
Area and Severity Index; PASI-50, 50% or greater reduction from baseline Psoriasis Area and Severity Index score; PASI-75, 75% or greater
reduction from baseline Psoriasis Area and Severity Index score; PASI-90, 90% or greater reduction from baseline Psoriasis Area and Severity
Index score; ScPGA, Scalp Physician Global Assessment (0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe); sPGA,
static Physician Global Assessment (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe); VAS, visual analog scale.
*P\ .0001 vs placebo.
ysPGA score of 0 (clear) or 1 (almost clear) with a $2-point reduction from baseline.
zPruritus VAS ranges from 0-100. Higher scores correspond to worse pruritus. Patients with a baseline value and $1 post baseline value are
included, n = 277 (placebo) and n = 559 (apremilast 30 mg BID).
xPatients with nail psoriasis (score of $1) at baseline. A reduction in the NAPSI indicated improvement.
kDecrease of $5 points in DLQI total score in patients with baseline DLQI total score[5. A reduction in score indicated improvement.
{Patients with ScPGA score of $3 at baseline.
#Other supportive end points were not included in the prespecified step-down procedure to test for statistical significance and are
presented descriptively.
**Decrease of $5 points in DLQI total score and PASI-50 achievement in patients with baseline DLQI total score[5.
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reported by more than 3 patients (Table III).
Exposure-adjusted incidence rates for SAEs were 6.1
for the 52-weekapremilast exposureperiod compared
with 7.5 for the 16-week placebo-controlled period
(period A). Incidence of SAEs was not driven by any
single preferred term or specific individual organ
toxicity. SAEs occurring in more than 1 patient
receiving apremilast for up to 52weekswere coronary
artery disease and nephrolithiasis (n = 3, each), and
urinary tract infection,acutemyocardial infarction,and
chronic obstructive pulmonary disease (n = 2, each)
(Table III). Each AE leading to discontinuation
occurred in less than 2% of patients (Table III).No tuberculosis reactivation or systemic vasculitis
was reported in the study. Changes in laboratory
parameters were transient and were not clinically
significant.
Body weight was measured in ESTEEM 1 at
regular intervals. During the long-term apremilast-
exposure period, themedian (mean) weight loss was
1.40 (2.08) kg, with 19.0% of patients having weight
loss greater than 5%. Weight decrease was reported
as an AE in 1.0% of patients treated with apremilast.
No patient reported an SAE of weight decrease and
no patient treated with apremilast discontinued
because of an AE of weight decrease. Weight loss
did not lead to any overt medical sequelae or
Fig 3. A, Mean percentage change in Nail Psoriasis Severity Index (NAPSI ) score. Reduction in
NAPSI score indicates improvement. Patients with a non-zero baseline value and 1 or more
postbaseline values are included. B, Proportion of patients achieving Scalp Physician Global
Assessment (ScPGA) score 0 (clear) or 1 (minimal) at week 16. Patients with ScPGA score of 3 or
more (moderate to very severe) at baseline and 1 or more postbaseline values are included.
BID, Twice a day. *P\ .0001 versus placebo.
Fig 4. A, Proportion of patients achieving 75% or greater reduction from baseline Psoriasis
Area and Severity Index (PASI ) score (PASI-75) response over 32 weeks. B, Mean percentage
improvement in PASI from baseline over 32 weeks. C, Mean change (mm) in pruritus visual
analog scale (VAS ) score from baseline over 32 weeks. Two-sided 95% confidence intervals are
shown. BID, Twice a day.
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Fig 5. Mean percentage change (2-sided 95% confidence intervals) in Psoriasis Area and
Severity Index (PASI ) over 52 weeks. A, Patients randomized to apremilast at baseline with 75%
or greater reduction from baseline PASI score (PASI-75) response at week 32 who were
rerandomized to apremilast (data for patients who were rerandomized to placebo during the
randomized treatment withdrawal phase are not shown). B, Patients randomized to placebo at
baseline who were PASI-75 responders at week 32 and entered the randomized treatment
withdrawal phase. Patient numbers begin at week 2. BID, Twice a day.
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period.
DISCUSSION
Two recent major surveys13,14 demonstrate that
many patients with psoriasis discontinue treatment
with conventional systemic agents or biologics,
despite considering their disease to be moderate to
severe, because of lack of tolerability, safety issues,
lack or loss of effectiveness, burden ofmonitoring, or
injections. Therefore, despite current treatment
options, there is an unmet medical need for newpsoriasis therapies that have an acceptable safety
profile and are effective.
Apremilast, an oral PDE4 inhibitor, provides a
novel therapeutic option for the treatment of patients
with moderate to severe plaque psoriasis. Its effects
on cyclic adenosine monophosphateeregulated
intracellular signaling, gene expression, and subse-
quent protein levels allow apremilast to modulate
the immune responses that cause the inflammation
associated with psoriasis.2,3 ESTEEM 1 is the first
phase III study confirming the efficacy of apremilast
in psoriasis. Apremilast demonstrated significant
Table III. Adverse events and laboratory abnormalities during the placebo-controlled period (wk 0-16) and the apremilast-exposure period (wk 0-52)
Patients
Placebo-controlled period
wk 0-16
Apremilast-exposure period
wk 0-52
Placebo n = 282 EAIR/100 patient-y Apremilast 30 mg BID n = 560 EAIR/100 patient-y Apremilast 30 mg BID n = 804 EAIR/100 patient-y
Overview, n (%)
$1 AE 157 (55.7) 322.6 388 (69.3) 534.3 633 (78.7) 329.2
$1 Severe AE 9 (3.2) 11.3 20 (3.6) 12.6 48 (6.0) 8.6
$1 Serious AE 8 (2.8) 10.1 12 (2.1) 7.5 34 (4.2) 6.1
$1 AE leading to drug withdrawal 9 (3.2) 11.4 29 (5.2) 18.3 59 (7.3) 10.5
$1 AE leading to death 1 (0.4)* 1.3 1 (0.2)y 0.6 1 (0.1)y 0.2
Reported by $5% of patients in any treatment group, n (%)
Diarrhea 20 (7.1) 26.6 105 (18.8) 78.2 150 (18.7) 31.6
Upper respiratory tract infection 21 (7.4) 27.3 57 (10.2) 37.6 143 (17.8) 28.8
Nausea 19 (6.7) 25.0 88 (15.7) 63.6 123 (15.3) 25.0
Nasopharyngitis 23 (8.2) 30.1 41 (7.3) 26.6 108 (13.4) 20.9
Tension headache 12 (4.3) 15.5 41 (7.3) 27.2 77 (9.6) 14.8
Headache 13 (4.6) 17.0 31 (5.5) 20.2 52 (6.5) 9.6
Leading to discontinuation in[1 patient in any treatment group, n (%)
Nausea 1 (0.4) 1.3 10 (1.8) 6.3 14 (1.7) 2.5
Diarrhea 1 (0.4) 1.3 7 (1.3) 4.4 10 (1.2) 1.8
Psoriasis 1 (0.4) 1.3 2 (0.4) 1.2 6 (0.7) 1.1
Vomiting 0 (0.0) 0.0 1 (0.2) 0.6 4 (0.5) 0.7
Dyspepsia 0 (0.0) 0.0 3 (0.5) 1.9 3 (0.4) 0.5
Headache 0 (0.0) 0.0 3 (0.5) 1.9 3 (0.4) 0.5
Tension headache 0 (0.0) 0.0 2 (0.4) 1.2 3 (0.4) 0.5
Dizziness 1 (0.4) 1.3 2 (0.4) 1.2 2 (0.2) 0.4
Migraine 0 (0.0) 0.0 2 (0.4) 1.2 2 (0.2) 0.4
Upper abdominal pain 0 (0.0) 0.0 2 (0.4) 1.2 2 (0.2) 0.4
Frequent bowel movements 0 (0.0) 0.0 2 (0.4) 1.2 2 (0.2) 0.4
Hematochezia 0 (0.0) 0.0 1 (0.2) 0.6 2 (0.2) 0.4
Psoriatic arthropathy 0 (0.0) 0.0 1 (0.2) 0.6 2 (0.2) 0.4
Asthenia 0 (0.0) 0.0 2 (0.4) 1.2 2 (0.2) 0.4
Fatigue 0 (0.0) 0.0 2 (0.4) 1.2 2 (0.2) 0.4
Squamous cell carcinoma of the skin 1 (0.4) 1.3 0 (0.0) 0.0 2 (0.2) 0.4
Serious AE occurring in[1 patient in any treatment group,z n (%)
Coronary artery disease 0 (0.0) 0.0 0 (0.0) 0.0 3 (0.4) 0.5
Nephrolithiasis 0 (0.0) 0.0 0 (0.0) 0.0 3 (0.4) 0.5
Urinary tract infection 0 (0.0) 0.0 0 (0.0) 0.0 2 (0.2) 0.4
Acute myocardial infarction 0 (0.0) 0.0 1 (0.2) 0.6 2 (0.2) 0.4
Chronic obstructive pulmonary disease 0 (0.0) 0.0 1 (0.2) 0.6 2 (0.2) 0.4
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Papp et al 47improvements in mean percentage change in PASI
score and in pruritus. PASI response was maintained
over 52 weeks with continued apremilast treatment.
In addition, apremilast demonstrated improvements
in nail and scalp psoriasis, both difficult-to-treat
forms of psoriasis.15,16 Most patients rerandomized
to placebo who lost PASI-75 response regained it
after apremilast reinitiation.
Apremilast has been studied in more than 4000
patients, and the safety profile is consistent across
indications.7,17-19 In this study, most AEs were mild or
moderate in severity and discontinuation rates
because of AEs were low. No new significant AEs
emerged compared with the placebo-controlled
period (period A), and rates did not appear to increase
with longer apremilast exposure. Incidence of SAEs
was low (2.1% for placebo and 2.8% for apremilast)
during the placebo-controlled period. Exposure-
adjusted incidence rates for SAEs did not increase
with longer apremilast exposure. No reactivation of
tuberculosis was reported in patients receiving apre-
milast. Changes in laboratory parameters were tran-
sient and were not clinically significant.
Data in this study were limited to 52 weeks and
do not provide long-term efficacy or safety
information. The results in this study population
might not generalize to those with nonplaque forms
of psoriasis, or those with comorbidities or medical
histories who were excluded from this study.
However, the study population herein appears
to be representative of the general plaque psoriasis
population given the prevalence of comorbidities.
Apremilast has demonstrated improvements in
the signs and symptoms of psoriatic arthritis and
improved physical function in patients with psoriatic
arthritis.17 In addition to psoriatic arthritis, apremilast
provides a novel therapeutic option to treat patients
with moderate to severe plaque psoriasis, whichmay
address documented patient concerns regarding
current treatment options. The findings from this
study indicate the clinical benefit of apremilast for up
to 52 weeks for the treatment of moderate to severe
plaque psoriasis. Most AEs were mild or moderate in
severity and discontinuation rates because of AEs
were low.
Conclusions
There is an unmet clinical need for new
psoriasis treatments. Apremilast is the first oral
PDE4 inhibitor to show efficacy in the management
of psoriasis. The results from this study showed
that apremilast significantly reduced the severity
of moderate to severe plaque psoriasis over 16
weeks, with responses maintained through 52
weeks of treatment. Most AEs were mild or
J AM ACAD DERMATOL
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48 Papp et almoderate in severity and discontinuation rates
because of AEs were low. Based on these data,
apremilast provides a novel therapeutic option for
the treatment of patients with moderate to severe
plaque psoriasis.
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